A small molecule, direct STAT3 inhibitor that inhibits the IL-6-induced SEAP expression with IC50 of 200-500 nM, blocks the binding of the activated STAT3 dimers to DNA.

A small molecule, full antagonist of CD4 that blocks gp120-CD4 interaction.

A small molecule, selective FOXO1 inhibitor that inhibits FOXO-dependent glucose production devoid of lipogenic activity in hepatocytes.

A small molecule, specific Measles virus (MeV) entry inhibitor with IC50 of 55 uM.

A small-molecule compound that disrupts the Golgi apparatus by inhibiting the activation of ADP-ribosylation factor 1 (ARF1).

A small-molecule inhibitor of bacterial ribosome rescue that exhibits broad-spectrum antimicrobial activity against bacteria grown in liquid culture.

A small-molecule inhibitor of Spindlin1 (SPIN1) with Kd of 2 uM.

A small-molecule inhibitor of Spindlin1 (SPIN1) with Kd of 4 uM.

A small-molecule inhibitor of STAT3.

OB-1 is a small-molecule inhibitor of STOML3 oligomerization that reverses pathological mechanical hypersensitivity in vivo; effectively inhibits the self-association of stomatin, STOML1 and STOML2 at 2 uM, but not podocin; reversibly reduces the sensitiv

A small-molecule inhibitor of the interaction of the C. glabrata Pdr1 activation domain with the C. glabrata Gal11A KIX domain with Ki of 18 uM.

A small-molecule inhibitor of type III secretion in Y. pseudotuberculosis, without affecting in vitro multiplication, causes a dose- and growth phase-dependent inhibition of C. trachomatis RB multiplication..

A small-molecule inhibitor that blocks the Aurora C/IκBα interaction (IC50=24.9 uM) and exerts antitumor activity in MDA-MB-231 breast cancer cells.

A small-molecule MAVS-dependent IRF3 agonist that shows antiviral activity against Flaviviridae, Filoviridae (Ebola virus), Orthomyxoviridae (influenza A virus), Arenaviridae (Lassa virus) and Paramyxoviridae (RSVs, Nipah virus).

A small-molecule partial agonist of CXCR7 (ACKR3)..

A small-molecule partial agonist of CXCR7 (ACKR3)..

A small-molecule partial agonist of CXCR7 (ACKR3)..

A small-molecule probe that selectively kills cells induced to express mutant RAS.

A small-molecule probe that selectively kills cells induced to express mutant RAS.

A small-molecule stabilizer of 14-3-3 protein-protein interactions that stabilizes the complex between 14-3-3 and the stress response regulator GCN1.

A small-molecule stabilizer of p53 mutant Y220C with Kd of 150 uM.

A small-molecule that inhibits Gβγ but not Gα signaling triggered upon activation of Gα(i)-βγ by the chemoattractant receptor OXE-R in both recombinant and human primary cells.

A small-molecule that specifically inhibits the interaction of β-catenin/LEF1 transcriptional complex in colon carcinoma cell lines.

BCI is A small-molecule, allosteric inhibitor of DUSP6 (dual-specificity phosphatase 6) with IC50 of 12.3 uM; also inhibits human DUSP1 with IC50 of 11.5 uM; suppresses the ERK-induced activation of Dusp6 and regulates heart size in zebrafish.

A small-molecule, allosteric inhibitor of Mycobacterium tuberculosis tryptophan synthase (TrpAB).

A small-molecule, fumaric acid ester (FAE) compound that is a prodrug of methyl hydrogen fumarate (also known as monomethyl fumarate), for the treatment of relapsing-remitting multiple sclerosis and plaque psoriasis..

A small-molecule, orally active inhibitor of TNF-α that reduces replication of HIV-1 (IC50=300 nM) and Mycobacterium tuberculosis in human cells.

A sodium channel inhibitor..

PF-915275 is a potent and selective inhibitor of human 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) (Ki ＜ 1 nM) with good preclinical pharmacokinetic properties.IC50 value: ＜ 1 nM (Ki)[2]Target: 11βHSD1in vitro: PF-915275 maintains potency in our cellular assay against human 11βHSD1 (HEK293, EC50 = 5 nM) and is selective against human 11βHSD2 (HEK293, 1.5% inhibition 10 μM). PF-915275 displays only weak affinity for the rodent choline transporter (Ki = 9.6 μM) and the hamster melatonin MT3 receptor (Ki = 9.6 μM) in the Cerep Bioprint screening panel. PF-915275 has good in vitro pharmacokinetic properties. In particular, PF-915275 is categorized as a low clearance compound (liver microsome assays) with high permeability (Caco2 assay). [2]in vivo: As a prelude to in vivo studies with PF-915275, the rat pharmacokinetic properties of this compound were determined. PF-915275 has an excellent pharmacokinetic profile characterized by low clearance, long half-life and good oral bioavailability. [2]

A specific anti-respiratory syncytial virus (RSV) agent with EC50 of 0.2 uM in plaque reduction assays.

A specific competitive RIPK1 inhibitor with IC50 of 1.03 uM, 100-fold less potent for RIPK3.

A specific HIF asparaginyl hydroxylase (FIH) inhibitor with Ki of 83 uM, but not HIF prolyl hydroxylase (>1 mM).

A specific inhibitor of MDA-9/Syntenin activity that inhibits MDA-9/Syntenin binding to EGFRvIII.

A specific inhibitor of mitochondrial Na(+)-Ca(2+) exchanger (mNCE) with IC50 of 1.5 uM in INS-1 cells.

A specific p38 MAPK inhibitor with IC50 of 0.6 uM.

A specific small molecule inhibitor of CCR5, inhibits HIV-1 entry..

A specific small molecule inhibitor of CCR5, inhibits HIV-1 entry..

A specific, competitive inhibitor of 14-3-3/ligand interactions with high affinity.

A specific, irreversible inhibitor of MLK-related kinase MRK (ZAK), does not inhibit Bcr-Abl.

A specific, membrane-permeable inhibitor of Gq signaling.

A specific, non-competitive, small molecule cytochrome c oxidase (CcO or complex IV) inhibitor with IC50 of 18.93 uM (CcO from human glioma).

A specific, small molecule Bax agonist that promotes Bax-dependent but not Bak-dependent apoptosis.

A spirocyclic fungal natural product used in treatment of fungal dermatophytes..

A squalene epoxidase inhibitor that is used as an antifungal agent.

A stable, orally active, non-prostanoid prostacyclin I2 (PGI2) mimetic and prostacyclin agonist with inhibitory activity against thromboxane A2 synthase.

A staurosporine analog that promotes embryonic stem cell (ESC) differentiation by inhibiting nuclear localization of the MYC transcription factor NME2, which in turn results in down-regulation of MYC transcription.

A steroid hormone with a weak androgenic effect, and an intermediate/prohormone of 11-ketotestosterone..

A synthesized pyrimidine analog that is a potent and selective anti-herpesvirus agent.

A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.

A synthetic amino acid that fuctions as a small molecule switch for activation of protein function through the site-specific incorporation.

A synthetic antimicrobial compound that antibacterial activity in vitro against various Gram-positive and Gram-negative bacteria, fungi and yeast..

A synthetic benzylamine antifungal that inhibits the synthesis of ergosterol by inhibiting squalene epoxidase.

A synthetic cannabinoid that acts as a potent, nonselective full agonist for the cannabinoid receptor with EC50 of 38 and 58 nM for CB1 and CB2, respectively.

A synthetic curcuminoid that selectively inhibits STAT3 phosphorylation, transcription, and DNA binding without affecting the expression of other active STATs.

A synthetic glucocorticoid corticosteroid..

A synthetic immunosuppressant that functions as a S1P1 receptor agonist.

A synthetic nonpsychoactive cannabinoid acid with potent analgesic and anti-inflammatory activity in vivo, binds directly and selectively to PPARγ.

A synthetic peptido-mimetic compound that inhibits MyD88 dimerization in a TIR-dependent manner.

A synthetic S-acyl derivative of thiamine (vitamin B1) that possesses anti-inflammatory effects.

A tailored WOBE437-derived diazirine-containing photoaffinity probe that irreversibly blocks membrane transport of both endocannabinoids.

A tetracycline antibiotic that acts by binding to the 30S ribosomal subunit to inhibit binding of aminoacyl tRNA which impairs protein synthesis by bacteria.

A thienopyridine-class antiplatelet agent that works by irreversibly inhibiting P2Y12 receptor on platelets.

A thiosemicarbazone that is used in association with other antimycobacterial agents in the initial and continuation phases of antituberculosis regimens. Thiacetazone containing regimens are less effective than the short-course regimen recommended by the I

A thymidine analogue nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV-2 isolates from treatment-naive individuals with EC50 of 30-81 nM.

A Toll-like receptor modulator.

A topical analgesic that possesses anti-inflammatory effect for treatment of skin diseases, such as acute and chronic eczema, contact dermatitis, diaper dermatitis, miliaria and atopic dermatitis..

A toxic byproduct, iminoquinone metabolite of acetaminophen that covalently binds to the active site of MIF.

A triazole antifungal agent that blocks the synthesis of ergosterol by inhibiting of the enzyme lanosterol 14α-demethylase and accumulation of methylated sterol precursors, more potent at inhibiting 14α-demethylase than itraconazole..

A tricyclic pentaglycosidic, antineoplastic antibiotic from Streptomyces strains that inhibits RNA and protein synthesis by adhering to DNA.

A tripeptide representing the Fas-C terminus that specifically blocks the interaction of Fap1 with Fas.

A triple monoamine reuptake inhibitor that inhibits the reuptake of [3H]serotonin, [3H]norepinephrine, and [3H]dopamine in HEK 293 cells expressing the corresponding human recombinant transporters (IC50 values of 12, 23, and 96 nM, respectively).

A triple monoamine reuptake inhibitor, inhibits the reuptake of 5-HT, norepinephrine and dopamine in HEK 293 cells with IC50 of 12, 23 and 96 nM, respectively.

A triterpenoid compound that potently and selectively inhibits JAK/STAT3 pathway, suppresses the levels of phosphotyrosine STAT3 in A549 cell with IC50 of 500 nM.

A tritium-labeled allosteric modulator of the human chemokine receptor CXCR3 with Kd of 1.08 nM.

A typical antipsychotic agent that displays an extremely strong binding affinity for dopamine D4 and serotonin 5-HT2 receptors..

A typical antipsychotic agent that displays an extremely strong binding affinity for dopamine D4 and serotonin 5-HT2 receptors..

A Tyrosine kinase inhibitor.

A tyrphostin AG17 analog that exihibits potent Src-K inhibitory activity with IC50 of 2.2 uM.

A veterinary anthelmintic with known proton ionophore activities.

A veterinary anthelmintic with known proton ionophore activities.

A VHL ligand for PROTAC..

A VHL ligand for PROTAC..

A VHL ligand for PROTAC..

A viral RNA-dependent RNA polymerase (RdRp) inhibitor that acts as a non-obligate RNA chain terminator.

A viral RNA-dependent RNA polymerase (RdRp) inhibitor that acts as a non-obligate RNA chain terminator.

A water-soluble derivative of 17-AAG and HSP90 inhibitor.

A water-soluble prodrug of triptolide that is highly effective in reducing pancreatic tumor growth and spread, and improving survival.

A widely used general anesthetic to induce and maintain anesthesia.

A xanthone derivative that fuctions as an EP and DP receptor antagonist.

A Zn2+-dependent pan-inhibitor of class I and class II HDACs with a long half-life (12h) in vivo.

A-1048400(A 1048400) is a novel potent, selective, orally active N-type and T-type calcium channel blocker with IC50 of 1.4 and 1.2 uM, respectively.

A-1155463 is a highly potent and selective BCL-XL inhibitor.

A-1210477 is a potent and selective MCL-1 inhibitor.

A12B4C3 (hPNKP inhibitor A12B4C3) is a specific, noncompetitive inhibitor of the human DNA repair enzyme polynucleotide kinase/phosphatase (hPNKP) with C50 of 60 nM, displays no inhibition of calcineurin and protein phosphatase-1 or APTX.

A-1331852 is a high affinity BH3 mimetic Ligand of BCL protein BCL-XL.

A1874 (A-1874) is a nutlin-based and BRD4-degrading PROTAC with DC50 of 32 nM (induce BRD4 degradation in cells).

A-196 is a potent and selective chemical inhibitor of SUV420H1 and SUV420H2 that inhibits the di- and trimethylation of H4K20me in multiple cell lines.

A-205804 is a potent and selective inhibitor of E-selectin and ICAM-1 expression with IC50 of 20 nM and 25 nM respectively.

A-317491 is a non-nucleotide P2X3 and P2X2/3 receptor antagonist, which inhibits calcium flux mediated by the receptors.

A-317567 (A317567) is a novel potent acid sensing ion channel (ASIC) blocker with IC50 of 2-30 uM.

A-357300 is a potent, selective, reversible MetAP2 inhibitor with IC50 of 0.12 uM, does not inhibit MetAP1 or leucine aminopeptidases at 10 uM.

A-366 is a potent and selective G9a/GLP histone lysine methyltransferase inhibitor (IC50 = 3.3 nM).

A-381393 is a potent and selective agonist of the dopamine D4 receptor.

A-395 potently inhibited the formation of H3K27me3 (via antagonizing EED in the trimeric PRC2 complex (EZH2:EED:SUZ12)) with IC50 = 34 ± 2 nM (Hill Slope = 0.7)

A-395N is the negative control compound of A-395, which is a potent, selective, and cellularly active PRC2 subunit EED inhibitor with Kd of 1.5 nM..

A-420983 is a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection.

A4250 (A-4250, Odevixibat) is a small molecule ileal bile acid transporter (IBAT) inhibitor for the treatment of cholestatic liver diseases including progressive familial intrahepatic cholestasis and NASH..

A-438079 HCl is a potent, and selective P2X7 receptor antagonist with pIC50 of 6.9.

A-484954 is a highly selective eukaryotic elongationfactor-2 (eEF2) inhibitor, with an IC50 of 280 nM.

A66 is a potent and specific p110α inhibitor with IC50 of 32 nM, >100 fold selectivity for p110α over other class-I PI3K isoforms.

A-674563 is a potent, orally available Akt1 inhibitor with an IC50 value of 11nM. Also displays activity against PKA and CDK2 with IC50 values of 16nM and 46nM respectively.

A-68930 is a potent, specific, orally bioavailable agonist of the D1 Dopamine receptor with EC50 of 2.5 nM.

A-740003 is potent, selective and competitive P2X7 receptor antagonist (IC50 values are 18 and 40 nM for rat and human receptors respectively).

A-769662 is a potent, reversible AMPK activator with EC50 of 0.8 μM, little effect on GPPase/FBPase activity.

A-779 is a peptide antagonist of the Mas receptor, also known as the angiotensin (1-7) (Ang (1-7)) receptor (IC50 = 0.3 nM in a radioligand binding assay).

A-790742 is a potent human immunodeficiency virus type 1 (HIV-1) protease inhibitor, with 50% effective concentrations ranging from 2 to 7 nM against wild-type HIV-1.

A-803467 is a selective NaV1.8 channel blocker with IC50 of 8 nM.

A-804598 is a novel, competitive, and selective P2X7 receptor antagonist with IC50 of 10 nM, 9 nM and 11 nM in rat, mouse and human P2X7 receptors respectively.

A83-01 is a selective inhibitor of TGF-β type I receptor ALK5 kinase, type I activin/nodal receptor ALK4 and type I nodal receptor ALK7 (IC50 values are 12, 45 and 7.5 nM respectively).

A-832234 is a potent, selective, reversible MetAP2 inhibitor with IC50 of 19 nM..

A-836339 (A836339) is a potent and selective cannabinoid CB2 receptor agonist with Ki of 0.64 and 0.76 nM for human and rat CB2 receptors, displays 425- and 189-fold selectivity over CB1 receptor, respectively.

A-867744 is a positive allosteric modulator of α7 nAChRs (IC50 values are 0.98 and 1.12 μM for human and rat α7 receptor ACh-evoked currents respectively, in X.

A939572 is a potent, and orally bioavailable SCD1 inhibitor with IC50 values of <4 nM and 37 nM for mSCD1 and hSCD1, respectively.

A-943931 dihydrochloride is a potent, selective antagonist of histamine H4 receptor (H4R) with binding pKi of 8.33 and 8.42 for hH4 and rH4, respectively.

A-943931 is a potent, selective antagonist of histamine H4 receptor (H4R) with binding pKi of 8.33 and 8.42 for hH4 and rH4, respectively.

A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with Ki of 1 nM and 1.5 nM, respectively.

AA 41612 is a potent, synthetic melanopsin antagonist with IC50 of 15.8 nM, attenuates melanopsin photocurrent in a dose-dependent manner.

aA highly potent, selective, non-competitive and centrally active mGluR1 antagonist with Ki of 0.34 nM.

AA-115 (APG 115) is a potent and orally active MDM2 inhibitor with Ki <1 nM, potently inhibits SJSA-1 cell growth with IC50 of 60 nM.

ATF6 agonist compound A147 is a specific, small molecule agonist of transcription factor ATF6, activates ATF6 and influences differentiation of stem cells.147 has broad antiviral activity against multiple DENV strains and serotypes and that the compound i

AA26-9 is a potent and broad spectrum serine hydrolase inhibitor.

AA-861 (Docebenone) is a potent, selective 5-Lipoxygenase (5-LO) inhibitor with IC50 of 0.8 uM.

AAD777 (NVP-AAD777.

AAE871 (AAE-871) is a potent type I kinase inhibitor of FLT3 with IC50 of 34 nM, potently inhibits proliferation of FLT3-ITD- and D835Y-expressing cells (IC50<10 nM) through selective inhibition of FLT3 kinase activity..

AAI-101 is a novel extended-spectrum β-lactamase inhibitor with activity against many β-lactamases, including some class A and class D carbapenemases.

AAK1 inhibitor 1 (SGC-AAK1-1) is a potent, selective inhibitor of AAK1 and BMP2K/BIKE ((BMP-2 inducible kinase)) that potently targets the ATP-binding site (AAK1 Ki =9.1 nM, BIKE Ki= 17 nM).

AAK1 inhibitor 25A is a potent, selective inhibitor of AAK1 and the closely related kinase BMP2K with Ki of 8 nM (AAK1).

AAL(S) is the chiral deoxy analog of the FDA approved drug FTY720, has been shown to inhibit proliferation and apoptosis in several cancer cell lines by activating protein phosphatase 2A (PP2A)..

AAL993 (ZK260253) is a potent, orally active VEGFR inhibitor with IC50 of 130, 23 and 18 nM for VEGFR-1, 2 and 3, respectively.

AB-423 is the first-generation Hepatitis B Virus Capsid Assembly inhibitor, which was generally safe and well tolerated in Phase 1 healthy volunteer studies.

AB680 (AB-680) is a highly potent, selective, reversible inhibitor of CD73 with Ki/IC50 of 4.9/70 pM (hCD73), displays > 10,000-fold selectivity against related ecto-nucleotidases (CD39, NTPDases 2/3/8) and a large panel of unrelated enzymes, receptors, a

Abacavir is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS.

Abametapir is the active ingredient of Xeglyze Lotion.

ABBV-744 is a BDII-selective BET bromodomain inhibitor that is being investigated to treat AML and metastic castration-resistant prostate cancer.BBV-744, a highly potent and selective inhibitor of the BD2 domain of BET family proteins with drug-like properties. In contrast to the broad range of cell growth inhibition induced by DbBi, the antiproliferative activity of ABBV-744 was largely, but not exclusively, restricted to cell lines of acute myeloid leukaemia and prostate cancer that expressed the full-length androgen receptor (AR). ABBV-744 retained robust activity in prostate cancer xenografts, and showed fewer platelet and gastrointestinal toxicities than the DbBi ABBV-07514.Analyses of RNA expression and chromatin immunoprecipitation followed by sequencing revealed that ABBV-744 displaced BRD4 from AR-containing super-enhancers and inhibited AR-dependent transcription, with less impact on global transcription compared with ABBV-075. These results underscore the potential value of selectively targeting the BD2 domain of BET family proteins for cancer therapy.

ABC1183 is a potent, selective, orally active GSK3α/β and CDK9 inhibitor with IC50 of 327/657 nM and 321 nM (CDK9/cyclin T1), shows growth inhibitory activity against a broad panel of cancer cell lines; decreases cell survival through G2/M arrest and modu

ABC294640 is an orally available, aryladamantane compound and selective inhibitor of sphingosine kinase-2 (SK2) with potential antineoplastic activity.

ABC99 is a potent, selective inhibitor of the Wnt-deacylating enzyme serine hydrolase NOTUM with IC50 of 13 nM, shows excellent selectivity across the serine hydrolase family.

ABD-1970 (ABD1970) is a highly potent, selective Monoacylglycerol lipase (MGLL) inhibitor with IC50 of 13 nM (human MGLL).

ABD328 (ABD-328) is an orally active, small molecule inhibitor of RANKL and TNF signalling that inhibits inflammation in vivo.

ABD345 is a small molecule inhibitor of RANKL signalling, inhibits TNF-induced NF-κB and MAPK activation and inflammation.

Abeprazan is an acid pump inhibitor..

Abiraterone (CB-7598) is a potent CYP17 inhibitor with IC50 of 2 nM.

Abiraterone (D4A) is an active metabolite of the CYP17A1 inhibitor abiraterone.

ABL127 (ML174) is a potent, selective, covalent inhibitor of protein methylesterase 1 (PME-1) with IC50 of 10 nM.

ABL-IN-29 is a picomolar ABL kinase inhibitor with IC50 of 0.06/0.11 nM for wt ABL and ABL T315I respectively..

ABMA is a novel broad-spectrum inhibitor of intracellular toxins and pathogens, efficiently protects cells against various toxins and pathogens including viruses, intracellular bacteria and parasite.

AB-MECA is a high affinity A3 adenosine receptor agonist, has high affinity for recombinant A1 and A3 receptors.

Abn-CBD (Abnormal Cannabidiol) is a selective agonist of GPR55 receptor with EC50 of 2.5 uM, shows no significant activity against CB1 and CB2 receptors (EC50>30 uM).

ABP-A3(ABP A3) is an inhibitor of ubiquitin conjugation that targets ubiquitin and Nedd8 E1 enzymes.

ABT-072 is a novel, orally bioavailable non-nucleoside HCV NS5B polymerase inhibitor with EC50 of 0.3 nM (GT1b).

ABT-080 is a potent FLAP inhibitor that inhibits ionophore-stimulated LTB(4) formation with with IC50 of 20 nM.

ABT-089 (Pozanicline) is a potent, selective α4β2 nAChR agonist with Ki of 16 nM.

ABT-100 (ABT100) is a highly selective, potent, orally bioavailable inhibitor of farnesyltransferase (FTase).

ABT-102 is a potent, highly selective, orally active TRPV1 antagonist that inhibits agonist-evoked increases in intracellular Ca(2+) levels with IC50 of 5-7 nM.

ABT-107 is a potent and selective α7 nAChR agonist with Ki of 0.2-0.6 nM for rat or human cortex α7 nAChRs.

ABT-199 is a Bcl-2-selective inhibitor with Ki < 0.010 nM.

ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤ 1 nM, respectively.

ABT-288 is a potent, selective and competitive antagonist of H3 receptor with Ki of 1.9/8.2 nM for human/rat H3 respectively.

ABT-333 is an NS5B non-nucleoside polymerase inhibitor.

ABT-594 represents a novel class of broad-spectrum analgesics whose primary mechanism of action is activation of the neuronal nicotinic acetylcholine receptors.

ABT-639 is a novel, peripherally acting, selective T-type Ca2+ channel blocker. ABT-639 blocks recombinant human T-type (Cav3.2) Ca2+ channels in a voltage-dependent fashion (IC50 = 2 μM) and attenuates LVA currents in rat DRG neurons (IC50 = 8 μM).

ABT-702 is a potent non-nucleoside adenosine kinase inhibitor (IC50 = 1.7 nM), selective over other sites of adenosine interaction (A1, A2A and A3 receptors, adenosine transporter and adenosine deaminase).

ABT-719 is a potent bacterial DNA gyrase inhibitor.

ABT-719 is a potent bacterial DNA gyrase inhibitor.

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM, respectively.

ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic sulfonamide agent with IC50 of about 1.5 and 3.4 μM in neuroblastoma and non-neuroblastoma cell lines, respectively.

ABT-869 is an ATP-competitive, multi-targeted RTK inhibitor that is completely effective against all members of the vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) receptor families.

ABTL0812 is a novel first-in-class, small molecule that inhibits the Akt/mTORC1 axis and shows antiproliferative effect on tumor cells.

ABX-1431 (ABX1431) is a highly potent, selective, orally available, CNS-penetrant monoacylglycerol lipase (MGLL) with IC50 of 14 nM (hMGLL).

ABX-1431 (ABX1431) is a highly potent, selective, orally available, CNS-penetrant monoacylglycerol lipase (MGLL) with IC50 of 14 nM (hMGLL).

ABX464 (ABX-464, ABX 464) is a novel class of anti-HIV small molecule targeting Rev-mediated viral RNA biogenesis, shows dose dependent inhibition of HIV-1 replication in stimulated PBMCs with IC50 of 0.1-0.5 uM.

AC 55541 is a potent and selective protease-activated receptor 2 (PAR2) agonist (pEC50 = 6.7) that displays no activity at other PAR subtypes or at over 30 other receptors involved in nociception and inflammation.

AC1903 is a specific and selective inhibitor of TRPC5 and has podocyte-protective properties. AC1903 does no effects on TRPC4 or TRPC6 currents and shows no off-target effects in kinase profiling assays. AC1903 suppresses severe proteinuria and prevents podocyte loss in focal segmental glomerulosclerosis (FSGS) rat model.

AC260584 is an M1 muscarinic receptor allosteric agonist with a pEC50 of 7.6.

AC261066 (AC-261066, AC261) is a potent, selective, orally available RARβ2 agonist with pEC50 of 8.1, displays selectivity over RARβ1, RARα and RARγ (pEC50=6.4, 6.2 and 6.3).

AC-263093 (AC263093) is a potent, functionally selective neuropeptide FF receptor type 2 (NPFFR2) agonist with pKi of 6.9.

AC264613 is a potent and selective protease-activated receptor 2 (PAR2) agonist (pEC50 = 7.5). Displays no activity at other PAR subtypes and exhibits no significant activity at over 30 other receptors implicated in nociception and inflammation.

AC-265347 is a calcimimetic acting agent and highly efficacious, orally active allosteric agonist (PAM) of CaSR with IC50 of 10 nM in PI hydrolysis assays.

AC-4-130 is a novel, potent STAT5 SH2 domain inhibitor, binds to and efficiently blocks STAT5 activation and subsequent transcriptional activity, shows high selectivity for STAT5 over STAT1 and STAT3.

AC5 inhibitor C90 is a novel potent, selective adenylyl cyclase type 5 (AC5) inhibitor with IC50 of 30 nM, >5-fold selectivity over AC2 and AC6 subtypes.

AC-55649 is a potent, highly isoform-selective agonist of human RARβ2 receptor, with a pEC50 of 6.9.

AC710, is a potent Globally Selective Inhibitor of Platelet-Derived Growth Factor Receptor-Family Kinases.

ACA is a cell permeable inhibitor of PLA2,reported to inhibit α-ketoisocaproic acid and glyceraldehyde-induced insulin secretion, as well as glucose-induced insulin secretion.

Acacetin is an O-methylated flavone found in Robinia pseudoacacia (black locust), Turnera diffusa (damiana),Betula pendula (silver birch),and in the fern Asplenium normale.

Acadesine results in accumulation of ZMP, which mimics the stimulating effect of AMP on AMPK and AMPK kinase. Phase 3.

Acalabrutinib (ACP-196) is a second-generation, selective, irreversible inhibitor of BTK.

Acalisib (GS-9820) is a potent and selective inhibitor of PI3Kδ with IC50 value of 12.7 nM.

Acarbose is the first identified α-glucosidase inhibitor.

Ac-DEVD-pNA is a colorimetric substrate for caspase-3 (CPP32) (Km=9.7μM) and related cysteine proteases.

Ac-DNLD-AMC is a fluorogenic caspase-3 substrate.